Amgen Q3 2026 Earnings Call Transcript
Key takeaways
- Amgen’s Q3 2026 results show solid revenue growth, a lift in 2026 , and strong cash flow, underscoring confidence in its product pipeline and market positioning.
guidance
What a company says it expects for future sales or profits — a forecast from the company, not a guarantee.
- Total revenues $10.4 billion (+8% )
YoY
Year over year — compared with the same period last year.
- Six key growth drivers grew 27%
YoY
Year over year — compared with the same period last year.
- Repatha sales $1.1 billion (+37%)
What happened
Amgen reported Q3 2026 results with total revenues up 8% Year over year — compared with the same period last year. What a company says it expects for future sales or profits — a forecast from the company, not a guarantee. Earnings per share — profit for one share of the company, in dollars.YoY
guidance
EPS
Why it matters
The stronger-than‑expected revenue growth and What a company says it expects for future sales or profits — a forecast from the company, not a guarantee.guidance
Short-term and longer-term
Short-term. In the next few days, watch for the impact of the raised 2026 What a company says it expects for future sales or profits — a forecast from the company, not a guarantee.guidance
Longer-term. Over the coming months, Amgen’s focus on high‑growth products like Repatha, Evenity, and Uplizna, combined with a robust pipeline, positions the company for sustained revenue expansion.
Words on this card
- non‑GAAP EPS
- Earnings per share calculated without certain accounting adjustments
- R&D
- Research and development, the spending on creating new products
- CapEx
- Capital expenditures, money spent on long‑term assets like factories
- Free cash flow
- Cash generated by the business after operating expenses and investments
- Guidance
- Company’s forecast for future financial performance
- EPS Learn
- Earnings per share — profit for one share of the company, in dollars.